Abstract
Src knockout mice show no detectable abnormalities in central nervous system (CNS) post-mitotic neurons, likely reflecting functional compensation by other Src family kinases. Cdk1- or Cdk5-dependent Ser75 phosphorylation in the amino-terminal Unique domain of Src, which shares no homology with other Src family kinases, regulates the stability of active Src. To clarify the roles of Src Ser75 phosphorylation in CNS neurons, we established two types of mutant mice with mutations in Src: phospho-mimicking Ser75Asp (SD) and non-phosphorylatable Ser75Ala (SA). In ageing SD/SD mice, retinal ganglion cell (RGC) number in whole retinas was significantly lower than that in young SD/SD mice in the absence of inflammation and elevated intraocular pressure, resembling the pathogenesis of progressive optic neuropathy. By contrast, SA/SA mice and wild-type (WT) mice exhibited no age-related RGC loss. The age-related retinal RGC number reduction was greater in the peripheral rather than the mid-peripheral region of the retina in SD/SD mice. Furthermore, Rho-associated kinase activity in whole retinas of ageing SD/SD mice was significantly higher than that in young SD/SD mice. These results suggest that Src regulates RGC survival during ageing in a manner that depends on Ser75 phosphorylation.
Introduction
Src, a membrane-associated 60 kDa tyrosine kinase, is expressed ubiquitously in mammalian tissues and is involved in the regulation of growth and post-mitotic cell behaviour1–3. The activation of Src occurs during fibroblast mitosis and is accompanied by the phosphorylation of serine and threonine in the amino-terminal Unique domain of the protein4. Cyclin-dependent kinase 1 (Cdk1; also known as p34cdc2), a critical cell-cycle regulator activated at the onset of mitosis, phosphorylates these mitosis-specific phosphorylation sites of Src5,6. Src functions in the regulation of mitosis by transducing Cdk1-initiated signals through phosphorylation cascades7. Cdk1-mediated phosphorylation of Src controls its mitotic activation that is modulated by Tyr527 phosphorylation8,9.
Although neurons are post-mitotic, they express high levels of Src, and a neuronal form of Src is expressed in some neural tissues of the brain and retina10,11. Src-specific activity is higher in neurons than in non-neuronal cells, suggesting that the protein plays important roles in neurons. For example, Src is involved in neurite extension, N-methyl-D-aspartate receptor-mediated synaptic transmission, and plasticity2,12, in addition to pathological processes, such as neurodegeneration, in the central nervous system (CNS)13. Nevertheless, Src knockout mice do not exhibit detectable abnormalities in neural tissues, although these mice do have shorter lifespans and develop osteopetrosis14,15. To date, however, studies of these animals have not yielded a full understanding of the physiological role of Src14, and it is possible that the observations in these knockout mice may reflect functional compensation by other tyrosine kinases related to Src15. Thus, to address this issue, we postulated that it would be useful to introduce point mutations into src at sites associated with the regulation of specific functions of Src.
One of the mitotic phosphorylation sites in human SRC is Ser75, located in the Unique domain of the protein. In human retinoblastoma cells, Ser75 is phosphorylated in a mitosis-independent manner16. This phosphorylation occurs in cultured neurons and some cultured tumour cells expressing neuronal forms of Src17. Previously, we showed using retinoblastoma cells that the kinase Cdk5/p35, which has the same consensus sequence as Cdk1, is responsible for phosphorylating Ser75 in the Unique domain, suggesting that Ser75 phosphorylation may play important roles in CNS neurons16,18.
Therefore, to gain a greater understanding of the role of Src in CNS neurons, we established two mutant mouse lines expressing one type of mutant Src each: one with a Ser75-to-Asp (SD) mutation, mimicking the phosphorylated form, and the other with a Ser75-to-Ala (SA) mutation, which lacks the phosphorylation site. Because these alleles harbour point mutations in the Unique domain, which shares no sequence similarity with other src family kinases, these mice were predicted to exhibit detectable abnormalities.
Results
Generation of SD and SA mutant mice
We established two lines of mice, each expressing one Src mutant: the phospho-mimicking Src S75D (SD) and the non-phosphorylatable Src S75A (SA). SD and SA mutant mice carried TCC → GAC and TCC → GCG mutations, respectively, in codon Ser75 of the mouse c-src gene.
To analyse the phenotypes of SD/SD and SA/SA mice, we intercrossed their respective heterozygotes. Tail DNA was amplified by polymerase chain reaction (PCR), and then allele-specific oligonucleotide (ASO) probe hybridisation was performed to determine the genotypes of the SD or SA littermates (Fig. 1a). To confirm transcription of the SD and SA mutant alleles, we isolated c-src cDNA by reverse transcription-PCR from wild-type (WT)/WT and homozygous mutant littermates. The mutations were verified by sequencing (Fig. 1b). The entire Src open reading frame was sequenced to confirm that no other mutations were present.
To examine Src kinase activity in SD and SA mutant mice, we performed autophosphorylation assays using immunoprecipitated Src from whole brain extracts of WT/WT and homozygous mutant mice. Like WT/WT mice, SD/SD and SA/SA mice expressed active Src (Fig. 1c). To confirm that phosphorylation was not occurring in SD and SA mutant mice, we performed immunoblots using an anti-Src (phospho-Ser75) antibody to detect Ser75 phosphorylation in brain or retina lysates following immunoprecipitation with the anti-Src antibody. Ser75 was phosphorylated in Src derived from WT/WT, but not in Src obtained from SD/SD or SA/SA mice (Fig. 1d).
To ensure that genetically altered and WT mice expressed the same level of Src protein, we assayed the retinal Src protein level by immunoblot analysis in the mice aged 6–8 months (Fig. 1e). No significant difference in the retinal Src protein level was detected between SD/SD or SA/SA mice and their WT counterparts. These results indicate that any changes observed in the SD/SD or SA/SA mutant mouse retina must be attributed to the SD or SA mutation itself, rather than to altered levels of Src protein.
Mice heterozygous or homozygous for the SD and SA mutations were viable, fertile and born at the expected Mendelian ratio. They exhibited no obvious abnormalities in appearance, and appeared to have a normal lifespan relative to their WT/WT littermates.
Retinal ganglion cell (RGC) loss in ageing SD/SD mutant mice
To examine the effect of the SD and SA mutations on retinal tissue, we performed histological analyses of neural retinas obtained from SD/SD and SA/SA mutant mice at younger (3–6 months old) and older (16–23 months old) ages. No structural abnormality was observed in the retinas of young and ageing SD/SD (Fig. 2a, left) and SA/SA mutants (Fig. 2a, right), as well as no inflammatory cell infiltration, neovascularisation, oedema or haemorrhage.
The Brn3a protein, a member of the Brn3 family of Pit-Oct-Unc-domain transcription factors, is specifically expressed by retinal ganglion cells (RGCs) in mice. Thus, Brn3a is a reliable protein marker for the identification and quantitation of RGCs in whole retina19–21. To investigate RGC loss, we quantitatively analysed Brn3a-positive RGC numbers in the mid-peripheral and peripheral regions of whole retinas (Fig. 2b,c) obtained from young and ageing mutant mice and compared these values with those obtained in young and ageing WT mice.
The RGC number of the whole region (mid-peripheral and peripheral regions combined) was reduced by 16% (P = 0.0171) in ageing SD/SD mice relative to that in young SD/SD mice, whereas WT/WT mice exhibited no age-related change in RGC number (Fig. 2d, left). By contrast, the RGC number in the retina of SA/SA mice was unchanged by age (Fig. 2d, right).
ROCK activity upregulation during ageing
The RhoA/Rho-associated kinase pathway plays roles in age-related neurodegeneration22,23. To elucidate the mechanism by which the SD mutation affects age-dependent RGC loss in whole retina, we analysed ROCK activity in whole retinas obtained from young and ageing WT/WT and SD/SD mice (Fig. 3a, left). ROCK activity in WT/WT did not change with age (P = 0.1323). By contrast, ROCK activity in whole retinas from ageing SD/SD mice was higher than that in both young SD/SD (48%; P = 0.0257) and ageing WT/WT mice (51%; P = 0.0216). These ROCK activity changes were inversely correlated with RGC number in whole retinas. The levels of ROCK activity in whole retinas obtained from SA/SA and WT/WT mice were similar at young and older ages, and the activity did not increase with age in SA/SA mice (P = 0.1736; Fig. 3a, right).
Because ROCK is a downstream effector of the Src-dependent phosphorylation cascade24, we investigated whether the increased ROCK activity observed in whole retinas obtained from SD/SD mutant mice was due to activation of ROCK kinase activity or to increases in the ROCK protein level (Fig. 3b,c). ROCK activity/protein ratios were compared between young and ageing WT/WT and SD/SD mice. The ratio in the retina was higher in young and ageing SD/SD mice than in young and aging WT mice (97%; P = 0.0055 and 65%; P = 0.0075, respectively). The ROCK ratio was not significantly affected by the age of either WT/WT or SD/SD mice (Fig. 3b). On the other hand, the ROCK ratio in retinas obtained from young SA/SA mice was similar to that in young WT/WT mice, suggesting that the SA/SA mutation did not activate ROCK kinase activity in whole retina (Supplementary Fig. S1, left). In contrast with these results, the level of retinal ROCK protein in young SD/SD, but not SA/SA (Supplementary Fig. S1, right) mutant mice was lower than that in young WT/WT mice (24%; P = 0.0105; Fig. 3c). The ROCK level increased with age in SD/SD mice (24%; P = 0.0355), whereas age did not affect the ROCK level in WT/WT mice (Fig. 3c). Thus, the SD/SD mutation increased ROCK kinase activity and was associated with an age-related increase in the ROCK protein level.
RGC losses in the mid-peripheral and peripheral regions of the retina
We compared the age-dependent RGC loss in the mid-peripheral and peripheral regions of the retina among the genotypes. Although no significant age-related change was observed in the number of RGCs in the mid-peripheral and peripheral regions of retinas obtained from WT/WT mice (P = 1.0000 and 1.0000; Fig. 4a, left), the retinas derived from the SD/SD mice exhibited a significant age-related decrease of 25% (P = 0.0008; Fig. 4a, left) in the number of RGCs in the peripheral but not in the mid-peripheral region (P = 0.3712; Fig. 4a, left). By contrast, ageing SA/SA mice exhibited no significant age-related change in RGC number in the mid-peripheral and peripheral regions relative to young SA/SA mice (P = 1.0000 and 1.0000; Fig. 4a, right); and their ageing WT counterparts exhibited no significant age-related change in RGC number in the mid-peripheral and peripheral regions (P = 0.6951 and 0.0644; Fig. 4a, right).
The number of RGCs in the peripheral region of the retinas in both young and ageing mice was lower than that in the mid-peripheral region of all genotypes (P < 0.0001; Fig. 4a). The ratios of the numbers of RGCs in the peripheral region relative to those in the mid-peripheral region (MP ratio) were compared between young and ageing mice. Only in SD/SD mice was the MP ratio in ageing animals significantly lower (17%) than that in young animals (P = 0.029; Fig. 4b, left). Consistent with this result, in SD/SD mice, the ratio of average RGC numbers in aged relative to young mice (young:old ratio) in the peripheral region (0.75) was 18% lower than that in the mid-peripheral region (0.91) (Fig. 4a, left). By contrast, no age-related change was observed for the MP ratio in SA/SA mice (Fig. 4b, right). The young:old ratio of average RGC numbers in the peripheral region (1.07) of SA/SA mice was similar to that in the mid-peripheral region (0.98) (Fig. 4a, right).
These results suggest that the RGCs in the peripheral region rather than those in the mid-peripheral region of the retina are preferentially damaged during ageing in SD/SD mice. By contrast, the SA/SA mutation did not promote RGC loss in the peripheral retina during ageing.
Intraocular pressure (IOP) elevation
Higher intraocular pressure (IOP) is considered to be the most important risk factor for the onset and deterioration of glaucoma. We, therefore, measured IOP in young and ageing mice of all three genotypes to investigate the relationship between RGC loss and IOP elevation in this model. To evaluate the relationship between RGC loss and IOP elevation, we measured IOP in young and ageing mice of all three genotypes (Fig. 5). We found no age-related difference in the IOP in either SD/SD or WT/WT mice (Fig. 5, left), indicating that the RGC loss in the SD mutant mouse was independent of IOP elevation. The IOP in ageing SA/SA mice was unchanged relative to that in young SA/SA mice and their WT counterparts (Fig. 5, right).
Discussion
This in vivo study demonstrated that the phospho-mimicking mutant Src S75D, but not the non-phosphorylatable mutant Src S75A, was associated with increased RGC loss in the retina, especially in the peripheral region, without an elevation in IOP, in ageing mice, suggesting that Ser75 phosphorylation regulates RGC survival during ageing. This age-related RGC loss was inversely related to ROCK activity in the whole retina.
In the neural retina, Src is expressed mainly in RGCs and photoreceptor cells, but its function remains obscure11,25. Because a good in vivo model to directly test the specific roles of Src while excluding the effects of redundant src family kinases is lacking15, the roles of Src in the RGC remain unknown. Ser75 in the Unique region of the src gene does not exist in other Src family kinase members and is highly conserved in Src, even in phylogenetically distant species. Our mutant mice carrying point mutations at Ser75 may overcome the challenge related to this redundancy. Moreover, unlike Src-null mutant mice14, the mutant mice developed here appeared to possess a normal lifespan and morphology. Thus, we believe that our mutant mice, carrying point mutations at Ser75, represent useful animal models for investigating the physiological roles of Src Ser75 phosphorylation in RGC survival.
The current mutant model showed age-related RGC loss without any morphological damage to other retinal components (Fig. 2a). Moreover, the IOPs of the mutants did not exceed those of their WT counterparts (Fig. 5). Taken together, these results suggest that the mutant mice could provide useful in vivo and in vitro systems for investigating the pathogenesis of age-related neurodegenerative diseases, such as normal tension glaucoma26, and developing therapies against these diseases.
Recent evidence suggests that downregulation of the small GTPase RhoA promotes survival and regeneration of RGC27. Inhibition of ROCK, one of the major downstream effectors of RhoA, increases neurite outgrowth and supports RGC survival28–32. In the present study, we showed that age-related RGC loss in SD/SD mice was inversely correlated with an age-related increase in the activity of ROCK, a downstream effector of Src, in the whole retina. Despite the fact that the retinas of young SD/SD mice contained approximately a 2-fold higher ROCK activity/ROCK protein ratio than WT mice, retinal ROCK activity in young SD/SD mice was not significantly different from that in young WT mice. This is because the ROCK protein level was lower in the retinas of young SD/SD mice, unlike the retinas of SA/SA mice (Fig. 3 and Supplementary Fig. S1). In young mice, ROCK protein levels may be downregulated in response to the increase in the ROCK ratio. However, with ageing, downregulation may decline, resulting in high ROCK activity and significant RGC loss in the retinas of ageing SD/SD mice. These results suggest that the SD mutation and ageing together affect RGC survival; that is, the SD gene mutation in these mice predisposes them to age-dependent RGC loss.
Some evidence has been obtained regarding the biochemical functions of Ser75 phosphorylation in the Src Unique domain33–35. In cultured human lens epithelial cells, ubiquitin-mediated degradation of activated Src is accelerated by Cdk5-dependent phosphorylation of Src Ser7536. This Cdk5-dependent suppression of active Src inhibits ROCK activity and results in cytoskeletal contraction and cell migration in lens epithelial cells37. Cdk5/p35 and ROCK are associated with survival and cytoskeletal activity of RGCs in vitro 38. Two possible pathways of Src-mediated downregulation of ROCK are proposed: one involves inactivation of RhoA through Src-dependent activation of p190RhoGAP37,39 and the other involves Src-dependent phosphorylation of ROCK40. Although the details of the molecular mechanisms remain to be clarified, the Src Ser75 mutation could affect fine-tuning of intracellular activity during ageing, resulting in deregulation of RGC survival and regeneration through ROCK.
We presented evidence for a difference in susceptibility to RGC loss in the mid-peripheral and peripheral retina: the RGCs in the periphery were preferentially reduced during ageing in SD/SD mutant mice. By contrast, the peripheral RGC loss was preferentially suppressed during ageing in SA/SA mutant mice. The mechanism is not known for this age-related difference in RGC loss susceptibility between the mid-peripheral and peripheral retina. The conditions to which the RGCs are exposed in the mid-periphery and periphery may differ; for example, the presence of glial cells41,42, expression of neurotrophic factors and their receptors43,44, redox status43,45,46, and axonal transport47,48 may differ. Future proteomics analyses of different regions of retina would lead to a better understanding of the mechanism49,50. In addition, specific ROCK activity or protein levels or both could be changed in relation to changes in Src Ser75 phosphorylation levels in the different regions of the retina.
Src Ser75 phosphorylation is a marker of the mitotic phase of the cell cycle. The G2/M regulator Cdk1 and its regulatory subunit cyclin B1 have been identified immunohistochemically in RGCs51. Aberrant expression or activation of the mitotic kinase in degenerating neurons has been investigated in studies aimed at understanding the mechanisms that induce cell death of post-mitotic neurons52–55. A large body of evidence implicates Cdk5 kinase in neurodegenerative diseases56–59. Expression of Cdk5 and its activator p35 changes over the course of development: Cdk5 expression is sustained in adulthood in both the inner nuclear layer and ganglion cell layer of the retina, but p35 expression is only sustained in the ganglion cell layer60. Furthermore, prolonged hyperactivation of Cdk5 has been inferred from Ca2+-activated, calpain-induced conversion of p35 to p25 in an acute glaucoma model61. Although some data exist suggesting the involvement of Cdk5 or Cdk1 kinase in retinal dysfunction51,53,60,61, their target molecules remain unknown. The results of the present study suggest that Src may be a candidate target molecule of active Cdk5 or Cdk1 during age-dependent neurodegeneration in vivo.
In conclusion, the phospho-mimicking SD mutant mice revealed that Src Ser75 phosphorylation regulates ageing-related RGC loss and that this is associated with altered ROCK kinase activity.
Methods
Animal experiments
Animal experiments were approved by the Animal Care and Use Committee of the University of Yamanashi and conducted in accordance with the University of Yamanashi’s Guide for Animal Experimentation and the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Analyses were performed after the SD and SA mutant mice were backcrossed six times to C57BL/6.
Generation of Mice
Knockin mice were produced using our previously reported gene-targeting procedure for the introduction of a point mutation into one allele of the c-src gene in mouse CCE embryonic stem (ES) cells by replacement and excision steps62,63. This procedure is feasible for generating mutant mice harbouring no exogenous sequence that may affect the expression of the targeted locus and closely linked genes.
The targeting vector was constructed as previously described63. It contained 9.0 kb of mouse c-src sequence, a 3.4 kb HSV-tk-neo cassette flanked by a 3.2 kb duplication containing a part of the c-src sequence. In the mutant constructs, exon 2 contained the 2 bp SD mutation (TCC→GAC) or the 2 bp SA mutation (TCC→GCG).
In our method, the replacement step involves homologous recombination between the targeting vector and the endogenous gene; this homologous recombination creates the mutation and inserts the selection cassette flanked by the duplication in one allele. After transfection of CCE ES cells with this vector, G418-resistant clones were selected and screened for homologous recombination by Southern blot analysis of genomic DNA63. The DNA was amplified by PCR63, and ASO probes specific for the normal or SD mutant allele were dot-blot hybridised to the PCR products to confirm heterozygosity, as described previously63. To detect the SA mutant allele, the PCR products were dot-blot hybridised at 54 °C with the ASO probe sa, which is identical to the SA mutant sequence (5′-TCTGCGGCGCGGTGAC-3′). The excision step excised the selection cassette by homologous recombination within the duplication at one allele. Heterozygous revertants bearing only the point mutation with no selection cassette were selected63 and screened for the excision by Southern blot analysis. ASO probe dot-blot hybridisation analyses were performed to confirm the presence of WT and mutant alleles, with no selectable marker, as described above.
Chimeras, generated by injection of a correctly reverted clone into blastocysts, were mated with C57BL/6 mice, and F1 heterozygotes were crossed to yield F2 offspring. Tail DNA was amplified by PCR, followed by ASO probe dot-blot hybridisation to identify homozygous mutants, as described above.
RNA isolation and reverse transcription-PCR
Total RNA was isolated from WT and homozygous mutant retinas using the TRIzol Reagent (Invitrogen) and the RNeasy Mini Kit (Qiagen). Reverse transcription-PCR reactions were performed using the PrimeScript RT reagent Kit (Takara).
Lysis of mouse tissues
A whole retina isolated from each mouse eye was disrupted and lysed by repetitive pipetting in 50 μL of RIPA buffer (10 mM Tris, pH 7.2, 0.15 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate and 0.1% sodium dodecyl sulphate) containing 1:100 dilutions of phosphatase inhibitor cocktail (Nacalai Tesque) and protease inhibitor cocktail (Sigma) at 4 °C for 30 min. Insoluble material was removed from the homogenate by centrifugation at 20,000 × g for 40 min at 4 °C. Whole brains were homogenised as described64. The homogenate was lysed in RIPA buffer containing phosphatase and protease inhibitor cocktails and then centrifuged, as described above.
Immunoblotting
Immunoblotting was performed essentially as described previously63. Briefly, proteins (25 µg per sample) were resolved on 8% sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) gels and electroblotted onto Hybond-ECL nitrocellulose membranes (Amersham). After blocking with 5% nonfat dry milk in Tris-buffered saline plus 0.05% Tween-20 (TBST), the membranes were incubated with a 1:2,000 dilution of mouse monoclonal anti-Src antibody clone 327 and a 1:2,000 dilution of rabbit monoclonal anti–β-tubulin (9F3) horseradish peroxidase (HRP)-conjugated antibody (Cell Signaling Technology) in TBST plus 2% nonfat dry milk, and then incubated with HRP-conjugated anti-mouse secondary antibody (1:4,000 dilution, GE Healthcare Life Sciences). The blots were visualised using ECL Plus western blotting detection reagents (Amersham). Images were acquired and quantitated using a LAS 1000 Image Analyzer (Fuji). Only values falling within the linear range were used for quantitative analysis.
Immunoprecipitation and kinase assays
Whole brain tissue lysates (about 1 mg of protein) containing nearly equal levels of Src protein were treated with 0.5 μg of normal mouse IgG and 20 μL of protein A/G agarose (Santa Cruz Biotechnology) for 30 min at 4 °C and then centrifuged. The supernatants were incubated with 3 μL of mouse monoclonal anti-Src antibody 327 for 2 h at 4 °C, and then precipitated with 25 μL of protein A/G agarose for 1.5 h at 4 °C. The immunoprecipitates were washed three times with RIPA buffer, once with buffer containing 10 mM Tris-HCl (pH 7.0) and 0.15 M NaCl, and once with kination buffer (20 mM Tris, pH 7.0, 10 mM MnCl2), and then subjected to immunoblot analysis as described above. Autophosphorylation assays were performed as previously described63 with minor modifications. In brief, the washed immunoprecipitates were incubated for 20 min at 30 °C in 40 μL of kination buffer containing 5 μCi of [γ-32P]ATP and 1 μM ATP. The reaction was stopped with RIPA buffer, and proteins were resolved by 8% SDS-PAGE. Autophosphorylation was detected using a BAS 2500 Image Analyzer (Fuji).
Detection of Src Ser75 phosphorylation
Src was immunoprecipitated with anti-Src antibody 327 from tissue lysate proteins (1 mg each), as described above. Immunoprecipitates were subjected to immunoblot analysis with an anti-Src (phospho-Ser75) antibody (1:750 dilution, Abcam). Blots were stripped and reprobed with the anti-Src antibody as described above.
Histological examination of mutant mouse retina
Eyes were removed from WT and mutant mice (aged 3–23 months) and then fixed in 4% paraformaldehyde in phosphate buffer (pH 7.4). The samples were embedded in paraffin, and 3 μm sections were cut through the optic nerve. The sections were deparaffinised in xylene and rehydrated in a series of graded ethanol solutions. After haematoxylin and eosin staining, the processed retinal sections were analysed using a light microscope (Olympus) at a magnification of 10 × or 20 × by an examiner who was blinded to all information regarding the samples.
Quantitation of RGCs
An eye was enucleated from each WT and mutant mouse (aged 3–23 months) and processed as a flattened whole mount using a published method65. Whole retinas were washed with PBS three times (5 min each) and permeabilised in 0.5% Triton-X 100 in PBS (0.1 M) for 15 min at room temperature. Retinas were washed three times with PBS and incubated with a mouse anti-Brn3a monoclonal antibody (1:250 dilution; MAB1585 clone 5A3.2; Millipore,) in blocking buffer (2% bovine serum albumin, 2% TritonX-100) at 4 °C overnight. Retinas were washed with PBS three times and incubated with a rabbit anti-mouse IgG secondary antibody conjugated to Alexa Fluor 568 (1:200 dilution, A-11061, Molecular Probes) for 3 h at room temperature. Retinas were washed three times with PBS and mounted onto slides with Fluorescent Mounting Medium (DAKO). Brn3a-positive RGCs were assessed by observing whole retinas under an epifluorescence microscope (BX50, Olympus) at a magnification of 20 × , and digitised images were compiled into a whole retina.
The number of Brn3a-positive RGCs was counted at two regions, namely, the mid-peripheral and peripheral regions of the retina, by an examiner who was blinded to all information regarding the samples. In each retina, the distance between the retinal margin and the optic nerve head was divided into thirds (Fig. 2b). The number of Brn3a-positive RGCs in the four boxed areas of equal size (400 × 400 μm) located at an equal distance of one-third from the optic nerve head (mid-periphery region) and at an equal distance of two-thirds from the optic nerve head (periphery region) were determined manually using the cell counter in ImageJ (Fig. 2b,c). The average value of the four boxed areas was used as the RGC number in the mid-periphery or periphery region of the retina of each mouse.
For investigations of the effect of ageing, samples from WT and mutant mice were categorised into two subgroups by age: young (3–6 months old) and ageing (16–23 months old).
ROCK activity assay
A whole retina isolated from each mouse eye was disrupted and lysed by repetitive pipetting in lysis buffer (20 mM Tris, pH 7.4, 1% Triton X-100), containing 1:100 dilutions of phosphatase inhibitor cocktail 2 (Sigma) and protease inhibitor cocktail (Sigma) at 4 °C for 15 min. Insoluble material was removed from the lysate by centrifugation at 20,000 × g for 20 min at 4 °C. The protein concentration of the lysate was determined with a Bradford protein assay (Bio-Rad). The immunoassay for ROCK activity was conducted in duplicate according to the manufacturer’s instructions (CycLex) using equal amounts of protein (3 μg). For visualisation, the HRP substrate reagent was added to the wells and incubated for 15 min at room temperature. The absorbance was measured using a spectrophotometric microplate reader (SpectraMAX 340, Molecular Devices) at a single wavelength of 450 nm. The activity level (mU per mg of retina protein) was calculated using recombinant Rho-kinase II (CycLex) as a standard. The activity was corrected by subtracting the value in the presence of an inhibitor of Rho-associated kinases, Y-27632 (Cat. No., 688001, Millipore), from that in the absence of the inhibitor.
For ROCK immunoblotting, whole retinal proteins (10 μg per sample) were resolved on 4–15% SDS-PAGE gels and transferred via the Trans-Blot Turbo blotting system (Bio-Rad Laboratories) to the 0.2 μm polyvinylidene difluoride membranes supplied in the Trans-Blot transfer packs. The filter was separated into two pieces, one containing ROCK proteins and the other containing β-tubulin. ROCK filters were incubated with an anti-ROCK-1/2 rabbit polyclonal antibody (1:600 dilution, Cat. No., 07–1458, Millipore) for 16 h at 4 °C and then incubated with a HRP-conjugated anti-rabbit (1:5,000 dilution, GE Healthcare Life Sciences) secondary antibody. The β-tubulin filters were incubated with a rabbit monoclonal anti–β-tubulin (1:2,000 dilution, 9F3) HRP-conjugated antibody for 16 h at 4 °C. The blots were visualised using ECL Prime western blotting detection reagents. Images were acquired and quantitated using a LAS 4000 Image Analyzer (GE Healthcare Life Sciences). Only values falling within the linear range were used for quantitative analysis. ROCK protein levels in each retina were normalised to those of β-tubulin.
IOP measurement
The IOP was measured in ketamine/xylazine-anesthetised mice between 14:00 h and 17:00 h with a rebound tonometer (TonoLab). The TonoLab tonometer provides a reliability score for each measured IOP value; according to the manufacturer’s recommendation, we used IOP values with good reliability. The IOP measurements were repeated until three reliable measurements were obtained, and the median of those three measurements was used as the IOP value for that set of measurements in each eye. The higher value of the right and left eyes was used as the IOP value for each mouse.
Statistical analysis
The results are presented as means ± s.d. and were analysed by unpaired two-tailed t-test, factorial ANOVA followed by Bonferroni post hoc tests or paired factorial ANOVA followed by Bonferroni post hoc tests, as appropriate. All statistical analyses were performed using Ekuseru–Toukei 2012 software (Social Survey Research Information). The P values <0.05 were considered statistically significant.
Data Availability
The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.
Electronic supplementary material
Acknowledgements
This work was supported by a Grant-in-Aid for Challenging Exploratory Research (to G.K., no. 25670729) from the Japan Society for the Promotion of Science, a Strategic (open-type) Project Grant from the University of Yamanashi (2010; to G.K.) and a Grant-in-Aid from the Cell Science Research Foundation (to S.M.). The authors thank Ikumi Saito for technical support in histological experiments.
Author Contributions
K.K. and G.K. contributed equally to this work. G.K. designed the experiments and coordinated the study. G.K., S.I. and S.M. generated the Src knockin mice. G.K. and K.K. performed the experiments and data analyses using the knockin mice. G.K. and K.K. wrote the paper. All authors read and approved the final manuscript.
Competing Interests
K.K. and G.K. have a Japanese patent (JP5938731) and have applied for an international patent (WO2012/124752). The remaining authors declare no competing financial interests.
Footnotes
Kenji Kashiwagi and Goro Kato contributed equally to this work.
Electronic supplementary material
Supplementary information accompanies this paper at 10.1038/s41598-017-16872-7.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Frame MC, Fincham VJ, Carragher NO, Wyke JA. v-Src’s hold over actin and cell adhesions. Nat. Rev. Mol. Cell Biol. 2002;3:233–245. doi: 10.1038/nrm779. [DOI] [PubMed] [Google Scholar]
- 2.Salter MW, Kalia LV. Src kinases: a hub for NMDA receptor regulation. Nat. Rev. Neurosci. 2004;5:317–328. doi: 10.1038/nrn1368. [DOI] [PubMed] [Google Scholar]
- 3.Schwartzberg PL. The many faces of Src: multiple functions of a prototypical tyrosine kinase. Oncogene. 1998;17:1463–1468. doi: 10.1038/sj.onc.1202176. [DOI] [PubMed] [Google Scholar]
- 4.Chackalaparampil I, Shalloway D. Altered phosphorylation and activation of pp60c-src during fibroblast mitosis. Cell. 1988;52:801–810. doi: 10.1016/0092-8674(88)90422-9. [DOI] [PubMed] [Google Scholar]
- 5.Morgan DO, Kaplan JM, Bishop JM, Varmus HE. Mitosis-specific phosphorylation of p60c-src by p34cdc2-associated protein kinase. Cell. 1989;57:775–786. doi: 10.1016/0092-8674(89)90792-7. [DOI] [PubMed] [Google Scholar]
- 6.Shenoy S, et al. Purified maturation promoting factor phosphorylates pp60c-src at the sites phosphorylated during fibroblast mitosis. Cell. 1989;57:763–774. doi: 10.1016/0092-8674(89)90791-5. [DOI] [PubMed] [Google Scholar]
- 7.Maller J, et al. Maturation-promoting factor and the regulation of the cell cycle. J. Cell Sci. Suppl. 1989;12:53–63. doi: 10.1242/jcs.1989.Supplement_12.6. [DOI] [PubMed] [Google Scholar]
- 8.Shenoy S, Chackalaparampil I, Bagrodia S, Lin PH, Shalloway D. Role of p34cdc2-mediated phosphorylations in two-step activation of pp60c-src during mitosis. Proc. Natl. Acad. Sci. USA. 1992;89:7237–7241. doi: 10.1073/pnas.89.15.7237. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Stover DR, Liebetanz J, Lydon NB. Cdc2-mediated modulation of pp60c-src activity. J. Biol. Chem. 1994;269:26885–26889. [PubMed] [Google Scholar]
- 10.Brugge JS, et al. Neurones express high levels of a structurally modified, activated form of pp60c-src. Nature. 1985;316:554–557. doi: 10.1038/316554a0. [DOI] [PubMed] [Google Scholar]
- 11.Sorge LK, Levy BT, Maness P. F. pp60c-src is developmentally regulated in the neural retina. Cell. 1984;36:249–257. doi: 10.1016/0092-8674(84)90218-6. [DOI] [PubMed] [Google Scholar]
- 12.Sinai L, Duffy S, Roder JC. Src inhibition reduces NR2B surface expression and synaptic plasticity in the amygdala. Learn. Mem. 2010;17:364–371. doi: 10.1101/lm.1765710. [DOI] [PubMed] [Google Scholar]
- 13.Khanna S, Roy S, Park HA, Sen CK. Regulation of c-Src activity in glutamate-induced neurodegeneration. J. Biol. Chem. 2007;282:23482–23490. doi: 10.1074/jbc.M611269200. [DOI] [PubMed] [Google Scholar]
- 14.Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693–702. doi: 10.1016/0092-8674(91)90499-O. [DOI] [PubMed] [Google Scholar]
- 15.Lowell CA, Soriano P. Knockouts of Src-family kinases: stiff bones, wimpy T cells, and bad memories. Genes Dev. 1996;10:1845–1857. doi: 10.1101/gad.10.15.1845. [DOI] [PubMed] [Google Scholar]
- 16.Kato G, Maeda S. Neuron-specific Cdk5 kinase is responsible for mitosis-independent phosphorylation of c-Src at Ser75 in human Y79 retinoblastoma cells. J. Biochem. 1999;126:957–961. doi: 10.1093/oxfordjournals.jbchem.a022540. [DOI] [PubMed] [Google Scholar]
- 17.Kato G, Maeda S. Novel phosphorylation at a mitotic site, serine 75, in human pp60c-src from unsynchronized human tumor cells having a spherical morphology. Biochem. Biophys. Res. Commun. 1995;216:619–629. doi: 10.1006/bbrc.1995.2667. [DOI] [PubMed] [Google Scholar]
- 18.Perez Y, Gairi M, Pons M, Bernado P. Structural characterization of the natively unfolded N-terminal domain of human c-Src kinase: insights into the role of phosphorylation of the unique domain. J. Mol. Biol. 2009;391:136–148. doi: 10.1016/j.jmb.2009.06.018. [DOI] [PubMed] [Google Scholar]
- 19.Chintala SK, Putris N, Geno M. Activation of TLR3 promotes the degeneration of retinal ganglion cells by upregulating the protein levels of JNK3. Invest. Ophthalmol. Vis. Sci. 2015;56:505–514. doi: 10.1167/iovs.14-15539. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Nadal-Nicolas FM, et al. Brn3a as a marker of retinal ganglion cells: qualitative and quantitative time course studies in naive and optic nerve-injured retinas. Invest. Ophthalmol. Vis. Sci. 2009;50:3860–3868. doi: 10.1167/iovs.08-3267. [DOI] [PubMed] [Google Scholar]
- 21.Rodriguez AR, de Sevilla Muller LP, Brecha NC. The RNA binding protein RBPMS is a selective marker of ganglion cells in the mammalian retina. J. Comp. Neurol. 2014;522:1411–1443. doi: 10.1002/cne.23521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Liu J, Gao HY, Wang XF. The role of the Rho/ROCK signaling pathway in inhibiting axonal regeneration in the central nervous system. Neural Regen Res. 2015;10:1892–1896. doi: 10.4103/1673-5374.170325. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Schmandke A, Schmandke A, Strittmatter SM. ROCK and Rho: biochemistry and neuronal functions of Rho-associated protein kinases. Neuroscientist. 2007;13:454–469. doi: 10.1177/1073858407303611. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Frame MC. Newest findings on the oldest oncogene; how activated src does it. J. Cell Sci. 2004;117:989–998. doi: 10.1242/jcs.01111. [DOI] [PubMed] [Google Scholar]
- 25.Jomary C, Cullen J, Jones SE. Inactivation of the Akt survival pathway during photoreceptor apoptosis in the retinal degeneration mouse. Invest. Ophthalmol. Vis. Sci. 2006;47:1620–1629. doi: 10.1167/iovs.05-1176. [DOI] [PubMed] [Google Scholar]
- 26.Iwase A, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641–1648. doi: 10.1016/j.ophtha.2004.03.029. [DOI] [PubMed] [Google Scholar]
- 27.Koch JC, Tonges L, Michel U, Bahr M, Lingor P. Viral vector-mediated downregulation of RhoA increases survival and axonal regeneration of retinal ganglion cells. Front. Cell. Neurosci. 2014;8:273. doi: 10.3389/fncel.2014.00273. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Ahmed Z, Berry M, Logan A. ROCK inhibition promotes adult retinal ganglion cell neurite outgrowth only in the presence of growth promoting factors. Mol. Cell. Neurosci. 2009;42:128–133. doi: 10.1016/j.mcn.2009.06.005. [DOI] [PubMed] [Google Scholar]
- 29.Cechmanek PB, Hehr CL, McFarlane S. Rho kinase is required to prevent retinal axons from entering the contralateral optic nerve. Mol. Cell. Neurosci. 2015;69:30–40. doi: 10.1016/j.mcn.2015.10.001. [DOI] [PubMed] [Google Scholar]
- 30.Lingor P, et al. Inhibition of Rho kinase (ROCK) increases neurite outgrowth on chondroitin sulphate proteoglycan in vitro and axonal regeneration in the adult optic nerve in vivo. J. Neurochem. 2007;103:181–189. doi: 10.1111/j.1471-4159.2007.04756.x. [DOI] [PubMed] [Google Scholar]
- 31.Lingor P, et al. ROCK inhibition and CNTF interact on intrinsic signalling pathways and differentially regulate survival and regeneration in retinal ganglion cells. Brain. 2008;131:250–263. doi: 10.1093/brain/awm284. [DOI] [PubMed] [Google Scholar]
- 32.Tan HB, Zhong YS, Cheng Y, Shen X. Rho/ROCK pathway and neural regeneration: a potential therapeutic target for central nervous system and optic nerve damage. Int J Ophthalmol. 2011;4:652–657. doi: 10.3980/j.issn.2222-3959.2011.06.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Amata I, et al. Multi-phosphorylation of the intrinsically disordered unique domain of c-Src studied by in-cell and real-time NMR spectroscopy. Chembiochem. 2013;14:1820–1827. doi: 10.1002/cbic.201300139. [DOI] [PubMed] [Google Scholar]
- 34.Amata I, Maffei M, Pons M. Phosphorylation of unique domains of Src family kinases. Front Genet. 2014;5:181. doi: 10.3389/fgene.2014.00181. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Perez Y, et al. Lipid binding by the Unique and SH3 domains of c-Src suggests a new regulatory mechanism. Sci. Rep. 2013;3:1295. doi: 10.1038/srep01295. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Pan Q, et al. Cdk5 targets active Src for ubiquitin-dependent degradation by phosphorylating Src(S75) Cell. Mol. Life Sci. 2011;68:3425–3436. doi: 10.1007/s00018-011-0638-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Tripathi BK, Zelenka PS. Cdk5-dependent regulation of Rho activity, cytoskeletal contraction, and epithelial cell migration via suppression of Src and p190RhoGAP. Mol. Cell. Biol. 2009;29:6488–6499. doi: 10.1128/MCB.01098-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Bermel C, et al. Combined inhibition of Cdk5 and ROCK additively increase cell survival, but not the regenerative response in regenerating retinal ganglion cells. Mol. Cell. Neurosci. 2009;42:427–437. doi: 10.1016/j.mcn.2009.09.005. [DOI] [PubMed] [Google Scholar]
- 39.Jeon CY, et al. Control of neurite outgrowth by RhoA inactivation. J. Neurochem. 2012;120:684–698. doi: 10.1111/j.1471-4159.2011.07564.x. [DOI] [PubMed] [Google Scholar]
- 40.Lee HH, et al. Src-dependent phosphorylation of ROCK participates in regulation of focal adhesion dynamics. J. Cell Sci. 2010;123:3368–3377. doi: 10.1242/jcs.071555. [DOI] [PubMed] [Google Scholar]
- 41.de Melo Reis RA, Cabral-da-Silva M, de Mello FG, Taylor JS. Muller glia factors induce survival and neuritogenesis of peripheral and central neurons. Brain Res. 2008;1205:1–11. doi: 10.1016/j.brainres.2008.02.035. [DOI] [PubMed] [Google Scholar]
- 42.Encinas M, et al. c-Src is required for glial cell line-derived neurotrophic factor (GDNF) family ligand-mediated neuronal survival via a phosphatidylinositol-3 kinase (PI-3K)-dependent pathway. J. Neurosci. 2001;21:1464–1472. doi: 10.1523/JNEUROSCI.21-05-01464.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Gupta VK, You Y, Klistorner A, Graham SL. Shp-2 regulates the TrkB receptor activity in the retinal ganglion cells under glaucomatous stress. Biochim. Biophys. Acta. 2012;1822:1643–1649. doi: 10.1016/j.bbadis.2012.07.016. [DOI] [PubMed] [Google Scholar]
- 44.Nakazawa T, et al. Comparative expression profiles of Trk receptors and Shc-related phosphotyrosine adapters during retinal development: potential roles of N-Shc/ShcC in brain-derived neurotrophic factor signal transduction and modulation. J. Neurosci. Res. 2002;68:668–680. doi: 10.1002/jnr.10259. [DOI] [PubMed] [Google Scholar]
- 45.Socodato R, et al. c-Src deactivation by the polyphenol 3-O-caffeoylquinic acid abrogates reactive oxygen species-mediated glutamate release from microglia and neuronal excitotoxicity. Free Radic. Biol. Med. 2015;79:45–55. doi: 10.1016/j.freeradbiomed.2014.11.019. [DOI] [PubMed] [Google Scholar]
- 46.Tezel G. Oxidative stress in glaucomatous neurodegeneration: mechanisms and consequences. Prog. Retin. Eye Res. 2006;25:490–513. doi: 10.1016/j.preteyeres.2006.07.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Fahy ET, Chrysostomou V, Crowston JG. Mini-Review: Impaired Axonal Transport and Glaucoma. Curr. Eye Res. 2016;41:273–283. doi: 10.3109/02713683.2015.1037924. [DOI] [PubMed] [Google Scholar]
- 48.Vidal-Sanz M, et al. Retinal neurodegeneration in experimental glaucoma. Prog. Brain Res. 2015;220:1–35. doi: 10.1016/bs.pbr.2015.04.008. [DOI] [PubMed] [Google Scholar]
- 49.Ethen CM, Reilly C, Feng X, Olsen TW, Ferrington DA. The proteome of central and peripheral retina with progression of age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2006;47:2280–2290. doi: 10.1167/iovs.05-1395. [DOI] [PubMed] [Google Scholar]
- 50.Okamoto H, et al. Comparative proteomic analyses of macular and peripheral retina of cynomolgus monkeys (Macaca fascicularis) Exp. Anim. 2010;59:171–182. doi: 10.1538/expanim.59.171. [DOI] [PubMed] [Google Scholar]
- 51.Lefevre K, Clarke PG, Danthe EE, Castagne V. Involvement of cyclin-dependent kinases in axotomy-induced retinal ganglion cell death. J. Comp. Neurol. 2002;447:72–81. doi: 10.1002/cne.10215. [DOI] [PubMed] [Google Scholar]
- 52.Konishi Y, Lehtinen M, Donovan N, Bonni A. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol. Cell. 2002;9:1005–1016. doi: 10.1016/S1097-2765(02)00524-5. [DOI] [PubMed] [Google Scholar]
- 53.Maas JW, Jr., et al. Apoptosis of central and peripheral neurons can be prevented with cyclin-dependent kinase/mitogen-activated protein kinase inhibitors. J. Neurochem. 1998;70:1401–1410. doi: 10.1046/j.1471-4159.1998.70041401.x. [DOI] [PubMed] [Google Scholar]
- 54.Wang W, et al. Neural cell cycle dysregulation and central nervous system diseases. Prog. Neurobiol. 2009;89:1–17. doi: 10.1016/j.pneurobio.2009.01.007. [DOI] [PubMed] [Google Scholar]
- 55.Yuan Z, et al. Activation of FOXO1 by Cdk1 in cycling cells and postmitotic neurons. Science. 2008;319:1665–1668. doi: 10.1126/science.1152337. [DOI] [PubMed] [Google Scholar]
- 56.Kanungo J, Zheng YL, Amin ND, Pant HC. Targeting Cdk5 activity in neuronal degeneration and regeneration. Cell. Mol. Neurobiol. 2009;29:1073–1080. doi: 10.1007/s10571-009-9410-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Patrick GN, et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 1999;402:615–622. doi: 10.1038/45159. [DOI] [PubMed] [Google Scholar]
- 58.Shah K, Lahiri DK. Cdk5 activity in the brain - multiple paths of regulation. J. Cell Sci. 2014;127:2391–2400. doi: 10.1242/jcs.147553. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Shelton SB, Johnson GV. Cyclin-dependent kinase-5 in neurodegeneration. J. Neurochem. 2004;88:1313–1326. doi: 10.1111/j.1471-4159.2003.02328.x. [DOI] [PubMed] [Google Scholar]
- 60.Hirooka K, et al. Developmental alteration of the expression and kinase activity of cyclin-dependent kinase 5 (Cdk5)/p35nck5a in the rat retina. J. Neurochem. 1996;67:2478–2483. doi: 10.1046/j.1471-4159.1996.67062478.x. [DOI] [PubMed] [Google Scholar]
- 61.Oka T, Tamada Y, Nakajima E, Shearer TR, Azuma M. Presence of calpain-induced proteolysis in retinal degeneration and dysfunction in a rat model of acute ocular hypertension. J. Neurosci. Res. 2006;83:1342–1351. doi: 10.1002/jnr.20827. [DOI] [PubMed] [Google Scholar]
- 62.Horie K, Maeda S, Nishiguchi S, Gottesman ME, Shimada K. A replacement vector used to introduce subtle mutations into mouse genes. Gene. 1995;166:197–204. doi: 10.1016/0378-1119(95)00613-3. [DOI] [PubMed] [Google Scholar]
- 63.Kato G, Maeda S. Production of mouse ES cells homozygous for Cdk5-phosphorylated site mutation in c-Src alleles. J. Biochem. 2003;133:563–569. doi: 10.1093/jb/mvg072. [DOI] [PubMed] [Google Scholar]
- 64.Haas S, et al. Expression of the myelin basic protein gene in transgenic mice expressing human neurotropic virus, JCV, early protein. Virology. 1994;202:89–96. doi: 10.1006/viro.1994.1325. [DOI] [PubMed] [Google Scholar]
- 65.Ganesh BS, Chintala SK. Inhibition of reactive gliosis attenuates excitotoxicity-mediated death of retinal ganglion cells. PLoS One. 2011;6:e18305. doi: 10.1371/journal.pone.0018305. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The datasets generated during and/or analysed during the current study are available from the corresponding author upon reasonable request.